首页 > 最新文献

Northern clinics of Istanbul最新文献

英文 中文
Hydroxytyrosol has a protective effect on the kidneys through dardarin and spexin. 羟基酪醇通过紫丹素和spexin对肾脏有保护作用。
IF 0.9 Pub Date : 2025-08-26 eCollection Date: 2025-01-01 DOI: 10.14744/nci.2025.97415
Nevin Kocaman, Elif Onat, Serhat Hancer

Objective: In this study, the possible role of dardarin and spexin in the protective effect of hydroxytyrosol (HT) against corn syrup-induced renal injury in rats was investigated.

Methods: Rats were categorized into four groups (n=6) as control, HT, corn syrup, and corn syrup+HT. Over 6 weeks, rats were administered water infused with 30% corn syrup, 4 ml/kg/day solution containing HT was administered, both independently and in conjunction with corn syrup, throughout the 6 weeks. The molecular parameters of dardarin and spexin in the renal tissue were assessed through histopathological examination. Biochemical parameters were also examined with the ELISA Method.

Results: In this study, it was observed that the dardarin and spexin levels increased in the control group as a result of the administration of corn syrup. After HT treatment, it was observed that the dardarin and spexin levels decreased. The increase in glucose, amylase, and lipase levels because of corn syrup consumption decreased with hydroxytyrosol consumption. The increase in erythrocyte extravasation, exudate accumulation, and fibrosis in kidney tissue observed as a result of corn syrup decreased as a result of HT administration.

Conclusion: It is thought that the protective effect of HT against damage to the renal due to corn syrup consumption may be mediated by dardarin and spexin.

目的:探讨达旦苷和玉米精苷在羟酪醇(HT)对玉米糖浆所致大鼠肾损伤的保护作用中的作用。方法:将大鼠分为对照组、HT组、玉米糖浆组、玉米糖浆+HT组4组(n=6)。在6周内,给大鼠注入30%玉米糖浆的水,在6周内单独或与玉米糖浆一起给药4 ml/kg/天的含HT溶液。通过组织病理学检查,测定大鼠肾组织中紫丹素和精尖素的分子参数。采用酶联免疫吸附法检测生化指标。结果:在本研究中,我们观察到,在对照组中,由于玉米糖浆的使用,达旦苷和大豆苷水平升高。经高温治疗后,可观察到紫丹素和spexin水平下降。葡萄糖、淀粉酶和脂肪酶水平的增加随着羟酪醇的摄入而降低。玉米糖浆引起的红细胞外渗、渗出物积聚和肾组织纤维化的增加随着HT的使用而减少。结论:认为羟色胺对玉米糖浆所致肾损伤的保护作用可能是通过紫丹素和大豆苷介导的。
{"title":"Hydroxytyrosol has a protective effect on the kidneys through dardarin and spexin.","authors":"Nevin Kocaman, Elif Onat, Serhat Hancer","doi":"10.14744/nci.2025.97415","DOIUrl":"10.14744/nci.2025.97415","url":null,"abstract":"<p><strong>Objective: </strong>In this study, the possible role of dardarin and spexin in the protective effect of hydroxytyrosol (HT) against corn syrup-induced renal injury in rats was investigated.</p><p><strong>Methods: </strong>Rats were categorized into four groups (n=6) as control, HT, corn syrup, and corn syrup+HT. Over 6 weeks, rats were administered water infused with 30% corn syrup, 4 ml/kg/day solution containing HT was administered, both independently and in conjunction with corn syrup, throughout the 6 weeks. The molecular parameters of dardarin and spexin in the renal tissue were assessed through histopathological examination. Biochemical parameters were also examined with the ELISA Method.</p><p><strong>Results: </strong>In this study, it was observed that the dardarin and spexin levels increased in the control group as a result of the administration of corn syrup. After HT treatment, it was observed that the dardarin and spexin levels decreased. The increase in glucose, amylase, and lipase levels because of corn syrup consumption decreased with hydroxytyrosol consumption. The increase in erythrocyte extravasation, exudate accumulation, and fibrosis in kidney tissue observed as a result of corn syrup decreased as a result of HT administration.</p><p><strong>Conclusion: </strong>It is thought that the protective effect of HT against damage to the renal due to corn syrup consumption may be mediated by dardarin and spexin.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"12 4","pages":"453-460"},"PeriodicalIF":0.9,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toxic metals in rheumatological diseases: A systematic review. 风湿性疾病中的有毒金属:系统综述。
IF 0.9 Pub Date : 2025-08-25 eCollection Date: 2025-01-01 DOI: 10.14744/nci.2024.58730
Jozélio Freire de Carvalho, Thelma L Skare

Heavy metals exposure might be linked to rheumatic diseases and has been studied in a few articles. The aim of this article is to review the studies that evaluated metal toxicity in rheumatological diseases. A systematic search of PubMed, Embase, and Scielo databases was performed, looking for articles on toxic metals and rheumatic diseases published between 1966 and March 2023. A total of 31 studies (1,559 RA and 4,308 patients with other rheumatic diseases) were included. Most patients were females, ranging from 4 to 62 years old. Although most studies showed higher concentrations of toxic metals in rheumatic diseases, a few showed a positive association with disease activity or severity of the conditions. This systematic review reveals the presence of toxic metals in patients with rheumatic disease. Screening for toxic metals may be elucidative in selected cases.

重金属接触可能与风湿病有关,一些文章对此进行了研究。本文旨在综述风湿性疾病中金属毒性评价的研究进展。对PubMed、Embase和Scielo数据库进行了系统搜索,寻找1966年至2023年3月期间发表的关于有毒金属和风湿病的文章。共纳入31项研究(1559例RA和4308例其他风湿病患者)。患者以女性居多,年龄4 ~ 62岁。虽然大多数研究显示风湿性疾病中有毒金属的浓度较高,但少数研究显示与疾病活动或病情严重程度呈正相关。本系统综述揭示了风湿性疾病患者中有毒金属的存在。筛选有毒金属可能是说明在选定的情况下。
{"title":"Toxic metals in rheumatological diseases: A systematic review.","authors":"Jozélio Freire de Carvalho, Thelma L Skare","doi":"10.14744/nci.2024.58730","DOIUrl":"10.14744/nci.2024.58730","url":null,"abstract":"<p><p>Heavy metals exposure might be linked to rheumatic diseases and has been studied in a few articles. The aim of this article is to review the studies that evaluated metal toxicity in rheumatological diseases. A systematic search of PubMed, Embase, and Scielo databases was performed, looking for articles on toxic metals and rheumatic diseases published between 1966 and March 2023. A total of 31 studies (1,559 RA and 4,308 patients with other rheumatic diseases) were included. Most patients were females, ranging from 4 to 62 years old. Although most studies showed higher concentrations of toxic metals in rheumatic diseases, a few showed a positive association with disease activity or severity of the conditions. This systematic review reveals the presence of toxic metals in patients with rheumatic disease. Screening for toxic metals may be elucidative in selected cases.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"12 4","pages":"527-536"},"PeriodicalIF":0.9,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating liver function test alterations in laparoscopic right adrenalectomy with different retractors. 不同牵开器对腹腔镜右肾上腺切除术肝功能改变的评价。
IF 0.9 Pub Date : 2025-08-19 eCollection Date: 2025-01-01 DOI: 10.14744/nci.2025.43788
Hilmi Anil Dincer, Ibrahim Alkan, Dogukan Dogu, Omer Cennet, Nezih Akkapulu, Ahmet Bulent Dogrul

Objective: Laparoscopic techniques have emerged as the preferred approach over traditional open surgery for the treatment of adrenal gland disorders. Right laparoscopic adrenalectomy (RLA) typically requires liver retraction for exposure, and various retractors can be used for this purpose. While studies have been conducted on liver injury during liver retraction in upper abdominal surgeries, no research has specifically addressed liver damage during laparoscopic adrenalectomy (LA). This study aims to evaluate the impact of two retractors used for liver retraction during RLA on liver function test results (LFTs) and their clinical significance.

Methods: This retrospective study included 87 LA patients who underwent surgery for adrenal gland pathology at our institution between 01/01/2010 and 04/30/2024. The patients were divided into two groups: RLA (n=42) and left LA (LLA) (n=45). The RLA patients were further categorized into two subgroups based on the retractor used: 5-blade retractor (FB) (n=22) and full ring retractor (GF) (n=20). Clinicopathological findings, operative outcomes, and laboratory test results were compared across groups.

Results: Postoperative levels of aspartate aminotransferase (AST), alanine aminotransferase, and alkaline phosphatase were significantly higher in the RLA groups (FB and GF) compared to the LLA group (p<0.001, p<0.001, p=0.001, respectively). Although no statistically significant difference was observed between groups, the median length of stay (LOS) was slightly shorter in the FB group (2 (2-3), p=0.058). There were no significant differences between FB and GF groups in terms of operation time, LFTs, complications, or mortality. Correlation analysis showed a statistically significant positive correlation between postoperative AST levels and lesion size (rho=0.31, p=0.045). Additionally, patients with functional adrenal pathologies had a significantly longer hospital stay compared to those with nonfunctional pathologies (2 (2-2.25) vs. 3 (2-3.5), p<0.001).

Conclusion: In RLA procedures, the LFT values were higher compared to LLA procedures. The effects of FB and GF retractors on surgical outcomes and LFT values were similar, indicating both retractors can be safely used during RLA surgeries. While no clinical impact was detected, caution is advised regarding potential liver injury during RLA procedures.

目的:腹腔镜技术已成为传统开放手术治疗肾上腺疾病的首选方法。右腹腔镜肾上腺切除术(RLA)通常需要肝牵开以暴露,各种牵开器可用于此目的。虽然已有关于上腹部手术中肝回缩过程中肝损伤的研究,但没有专门针对腹腔镜肾上腺切除术(LA)过程中肝损伤的研究。本研究旨在评价RLA中两种牵开器对肝功能检查结果(LFTs)的影响及其临床意义。方法:本回顾性研究纳入了2010年1月1日至2024年4月30日在我院接受肾上腺病理手术的87例LA患者。将患者分为左LA组(n=45)和右LA组(n=42)。根据使用的牵开器将RLA患者进一步分为两组:5刃牵开器(FB) (n=22)和全环牵开器(GF) (n=20)。比较两组患者的临床病理表现、手术结果和实验室检查结果。结果:与LLA组相比,RLA组(FB和GF)术后天冬氨酸转氨酶(AST)、丙氨酸转氨酶和碱性磷酸酶水平显著高于LLA组(p结论:RLA手术中LFT值高于LLA手术。FB和GF牵开器对手术结果和LFT值的影响相似,表明两种牵开器在RLA手术中都可以安全使用。虽然没有发现临床影响,但建议在RLA过程中注意潜在的肝损伤。
{"title":"Evaluating liver function test alterations in laparoscopic right adrenalectomy with different retractors.","authors":"Hilmi Anil Dincer, Ibrahim Alkan, Dogukan Dogu, Omer Cennet, Nezih Akkapulu, Ahmet Bulent Dogrul","doi":"10.14744/nci.2025.43788","DOIUrl":"10.14744/nci.2025.43788","url":null,"abstract":"<p><strong>Objective: </strong>Laparoscopic techniques have emerged as the preferred approach over traditional open surgery for the treatment of adrenal gland disorders. Right laparoscopic adrenalectomy (RLA) typically requires liver retraction for exposure, and various retractors can be used for this purpose. While studies have been conducted on liver injury during liver retraction in upper abdominal surgeries, no research has specifically addressed liver damage during laparoscopic adrenalectomy (LA). This study aims to evaluate the impact of two retractors used for liver retraction during RLA on liver function test results (LFTs) and their clinical significance.</p><p><strong>Methods: </strong>This retrospective study included 87 LA patients who underwent surgery for adrenal gland pathology at our institution between 01/01/2010 and 04/30/2024. The patients were divided into two groups: RLA (n=42) and left LA (LLA) (n=45). The RLA patients were further categorized into two subgroups based on the retractor used: 5-blade retractor (FB) (n=22) and full ring retractor (GF) (n=20). Clinicopathological findings, operative outcomes, and laboratory test results were compared across groups.</p><p><strong>Results: </strong>Postoperative levels of aspartate aminotransferase (AST), alanine aminotransferase, and alkaline phosphatase were significantly higher in the RLA groups (FB and GF) compared to the LLA group (p<0.001, p<0.001, p=0.001, respectively). Although no statistically significant difference was observed between groups, the median length of stay (LOS) was slightly shorter in the FB group (2 (2-3), p=0.058). There were no significant differences between FB and GF groups in terms of operation time, LFTs, complications, or mortality. Correlation analysis showed a statistically significant positive correlation between postoperative AST levels and lesion size (rho=0.31, p=0.045). Additionally, patients with functional adrenal pathologies had a significantly longer hospital stay compared to those with nonfunctional pathologies (2 (2-2.25) vs. 3 (2-3.5), p<0.001).</p><p><strong>Conclusion: </strong>In RLA procedures, the LFT values were higher compared to LLA procedures. The effects of FB and GF retractors on surgical outcomes and LFT values were similar, indicating both retractors can be safely used during RLA surgeries. While no clinical impact was detected, caution is advised regarding potential liver injury during RLA procedures.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"12 4","pages":"387-395"},"PeriodicalIF":0.9,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric inflammatory bowel diseases: Effects of disease and treatment regimens on growth and puberty. 儿童炎症性肠病:疾病和治疗方案对生长和青春期的影响。
IF 0.9 Pub Date : 2025-08-19 eCollection Date: 2025-01-01 DOI: 10.14744/nci.2024.93342
Eda Gurler, Nelgin Gerenli, Coskun Celtik, Fatma Dursun, Heves Kirmizibekmez

Objective: Inflammatory bowel diseases (IBD) are lifelong conditions that exhibit periods of remission and exacerbation. In addition to gastrointestinal manifestations, they can also cause growth retardation and disorders of puberty in children. The objective of this study was to evaluate the effects of the disease and the treatment regimens on growth and puberty in children and adolescents with IBD.

Methods: A retrospective screening of patients aged 2 to 18 years with a minimum of six months of follow-up due to inflammatory bowel disease (IBD) between January 2016 and April 2022 was conducted. The growth parameters were compared between disease groups, gender groups, disease activity and level of inflammation groups, and treatment regimen groups. The effects of treatment protocols on growth were evaluated by comparing the data before and after treatment, and the pubertal status of patients was evaluated by comparing them with healthy children.

Results: A total of 58 patients were evaluated, comprising 29 individuals with Crohn's Disease (CD) and 29 with ulcerative colitis (UC). The growth and pubertal development of patients at the time of diagnosis did not differ based on gender or the specific disease type. A negative deviation from the target height was observed to be more prevalent in patients with Crohn's disease. Following treatment, patients exhibited a significant improvement in weight and BMI SDS, although no significant change in height SDS was observed. In comparison to healthy Turkish children, the patients exhibited a delayed pubertal progression, despite the normal onset of puberty.

Conclusion: Children and adolescents with IBD exhibited no significant adverse effects on linear growth at diagnosis or during the follow-up period, regardless of the primary disease and the treatment protocols. This was likely due to their timely diagnosis and successful treatment. It is important to monitor puberty, as it may progress more slowly or even cease in these patients compared to healthy children.

目的:炎症性肠病(IBD)是一种表现出缓解期和加重期的终身疾病。除胃肠道表现外,还可引起儿童发育迟缓和青春期障碍。本研究的目的是评估疾病和治疗方案对患有IBD的儿童和青少年的生长和青春期的影响。方法:回顾性筛查2016年1月至2022年4月期间2至18岁炎症性肠病(IBD)患者,随访至少6个月。比较不同疾病组、不同性别组、不同疾病活动度及炎症程度组、不同治疗方案组的生长参数。通过比较治疗前后的数据来评估治疗方案对生长的影响,并通过与健康儿童的比较来评估患者的青春期状态。结果:共评估了58例患者,其中29例患有克罗恩病(CD), 29例患有溃疡性结肠炎(UC)。在诊断时,患者的生长和青春期发育没有基于性别或特定疾病类型的差异。与目标身高的负偏差在克罗恩病患者中更为普遍。治疗后,患者的体重和BMI SDS均有显著改善,但身高SDS未见显著变化。与健康的土耳其儿童相比,患者表现出青春期发育的延迟,尽管青春期正常开始。结论:无论原发疾病和治疗方案如何,患有IBD的儿童和青少年在诊断时或随访期间对线性生长没有明显的不良影响。这可能是由于他们的及时诊断和成功治疗。监测青春期是很重要的,因为与健康儿童相比,这些患者的青春期进展可能更慢,甚至停止。
{"title":"Pediatric inflammatory bowel diseases: Effects of disease and treatment regimens on growth and puberty.","authors":"Eda Gurler, Nelgin Gerenli, Coskun Celtik, Fatma Dursun, Heves Kirmizibekmez","doi":"10.14744/nci.2024.93342","DOIUrl":"10.14744/nci.2024.93342","url":null,"abstract":"<p><strong>Objective: </strong>Inflammatory bowel diseases (IBD) are lifelong conditions that exhibit periods of remission and exacerbation. In addition to gastrointestinal manifestations, they can also cause growth retardation and disorders of puberty in children. The objective of this study was to evaluate the effects of the disease and the treatment regimens on growth and puberty in children and adolescents with IBD.</p><p><strong>Methods: </strong>A retrospective screening of patients aged 2 to 18 years with a minimum of six months of follow-up due to inflammatory bowel disease (IBD) between January 2016 and April 2022 was conducted. The growth parameters were compared between disease groups, gender groups, disease activity and level of inflammation groups, and treatment regimen groups. The effects of treatment protocols on growth were evaluated by comparing the data before and after treatment, and the pubertal status of patients was evaluated by comparing them with healthy children.</p><p><strong>Results: </strong>A total of 58 patients were evaluated, comprising 29 individuals with Crohn's Disease (CD) and 29 with ulcerative colitis (UC). The growth and pubertal development of patients at the time of diagnosis did not differ based on gender or the specific disease type. A negative deviation from the target height was observed to be more prevalent in patients with Crohn's disease. Following treatment, patients exhibited a significant improvement in weight and BMI SDS, although no significant change in height SDS was observed. In comparison to healthy Turkish children, the patients exhibited a delayed pubertal progression, despite the normal onset of puberty.</p><p><strong>Conclusion: </strong>Children and adolescents with IBD exhibited no significant adverse effects on linear growth at diagnosis or during the follow-up period, regardless of the primary disease and the treatment protocols. This was likely due to their timely diagnosis and successful treatment. It is important to monitor puberty, as it may progress more slowly or even cease in these patients compared to healthy children.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"12 4","pages":"396-403"},"PeriodicalIF":0.9,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497906/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TFE3 immunohistochemistry in renal cell carcinomas: Does the clone really matter? 肾细胞癌的TFE3免疫组化:克隆真的重要吗?
IF 0.9 Pub Date : 2025-08-14 eCollection Date: 2025-01-01 DOI: 10.14744/nci.2024.19794
Tuba Dilay Kokenek Unal, Merve Meryem Kiran, Nuran Sungu, Aylin Yazgan, Berrak Gumuskaya

Objective: TFE3 rearranged carcinomas constitute 5% of malignant tumours of the kidney in adults. TFE3 immunohistochemistry plays a crucial role in the diagnosis. TFE3 positivity in the appropriate histological context supports the diagnosis of Xp11 translocation renal cell carcinomas. However, there isn't any standardized approach to performing and interpreting immunohistochemical staining.

Methods: A total of 51 renal cell carcinomas are included in the study. In this study, we compared the expression profiles of two different anti-TFE3 antibody clones (MRQ37, Cell Marque, and IHC627, GeneAbTM) on renal cell carcinoma samples that have conflicting morphologies and assessed the overall performance of these clones to identify TFE3 rearranged carcinomas.

Results: There was a statistically significant difference in terms of immunohistochemical staining with TFE3-MRQ37 clone between TFE3 rearranged renal cell carcinomas and other subtypes, while no significant difference was found in staining with TFE3-IHC672. 47% of cases were stained with the TFE3-IHC672 clone and 9.8 % of cases were stained with the TFE3-MRQ37 clone at different staining intensities and proportions.

Conclusion: The TFE3-MRQ37 clone is easier to interpret because of the absence of background staining and is more reliable in identifying TFE3 rearranged renal cell carcinomas. However, because of various sensitivity and specificity rates, and immunoreactivity in many subtypes of renal cell carcinomas, there is a need for a standardised approach for TFE3 immunohistochemistry for diagnostic use in TFE3-tRCCs.

目的:TFE3重排癌占成人肾脏恶性肿瘤的5%。TFE3免疫组化在诊断中起着至关重要的作用。在适当的组织学背景下TFE3阳性支持Xp11易位性肾细胞癌的诊断。然而,没有任何标准化的方法来执行和解释免疫组织化学染色。方法:51例肾细胞癌纳入研究。在这项研究中,我们比较了两种不同的抗TFE3抗体克隆(MRQ37, Cell Marque和IHC627, GeneAbTM)在形态冲突的肾细胞癌样本中的表达谱,并评估了这些克隆在识别TFE3重排癌中的总体表现。结果:TFE3重排肾细胞癌与其他亚型的TFE3- mrq37克隆免疫组化染色差异有统计学意义,而TFE3- ihc672染色差异无统计学意义。47%的病例用TFE3-IHC672克隆染色,9.8%的病例用不同染色强度和比例的TFE3-MRQ37克隆染色。结论:TFE3- mrq37克隆由于没有背景染色,更容易解释,在鉴别TFE3重排肾细胞癌方面更可靠。然而,由于在许多肾细胞癌亚型中存在不同的敏感性和特异性以及免疫反应性,因此需要一种标准化的TFE3免疫组织化学方法用于TFE3- trcc的诊断。
{"title":"TFE3 immunohistochemistry in renal cell carcinomas: Does the clone really matter?","authors":"Tuba Dilay Kokenek Unal, Merve Meryem Kiran, Nuran Sungu, Aylin Yazgan, Berrak Gumuskaya","doi":"10.14744/nci.2024.19794","DOIUrl":"10.14744/nci.2024.19794","url":null,"abstract":"<p><strong>Objective: </strong>TFE3 rearranged carcinomas constitute 5% of malignant tumours of the kidney in adults. TFE3 immunohistochemistry plays a crucial role in the diagnosis. TFE3 positivity in the appropriate histological context supports the diagnosis of Xp11 translocation renal cell carcinomas. However, there isn't any standardized approach to performing and interpreting immunohistochemical staining.</p><p><strong>Methods: </strong>A total of 51 renal cell carcinomas are included in the study. In this study, we compared the expression profiles of two different anti-TFE3 antibody clones (MRQ37, Cell Marque, and IHC627, GeneAbTM) on renal cell carcinoma samples that have conflicting morphologies and assessed the overall performance of these clones to identify TFE3 rearranged carcinomas.</p><p><strong>Results: </strong>There was a statistically significant difference in terms of immunohistochemical staining with TFE3-MRQ37 clone between TFE3 rearranged renal cell carcinomas and other subtypes, while no significant difference was found in staining with TFE3-IHC672. 47% of cases were stained with the TFE3-IHC672 clone and 9.8 % of cases were stained with the TFE3-MRQ37 clone at different staining intensities and proportions.</p><p><strong>Conclusion: </strong>The TFE3-MRQ37 clone is easier to interpret because of the absence of background staining and is more reliable in identifying TFE3 rearranged renal cell carcinomas. However, because of various sensitivity and specificity rates, and immunoreactivity in many subtypes of renal cell carcinomas, there is a need for a standardised approach for TFE3 immunohistochemistry for diagnostic use in TFE3-tRCCs.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"12 4","pages":"438-444"},"PeriodicalIF":0.9,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of metformin on cell proliferation and apoptosis in steatosis HepG2 cell model. 二甲双胍对脂肪变性HepG2细胞增殖和凋亡的影响。
IF 0.9 Pub Date : 2025-08-11 eCollection Date: 2025-01-01 DOI: 10.14744/nci.2024.49775
Ayse Melek Tanriverdi Bademci, Banu Aydin, Hulya Cabadak

Objective: Metformin, which is commonly recommended drug for managing type II diabetes, has been reported to have anti-cancer properties and may improve the prognosis of some malignancies. Epidemiology studies have shown improved survival in cancer patients using metformin. However, the mechanism behind this phenomenon remains incompletely understood. In our study, Our objective was to investigate how metformin influences the proliferation and apoptosis of hepatocellular carcinoma cells induced with steatosis via palmitic acid and oleic acid.

Methods: We established an in vitro cellular model of non-alcoholic fatty liver disease by inducing lipid accumulation in HepG2 cells through the use of oleic acid and palmitic acid. Oil Red O staining was conducted to observe the distribution of intracellular lipid droplets. Cell proliferation were detected using the BrdU cell proliferation detection kit. Protein expressions were detected by western blot method techniques.

Results: We found that metformin reduced cell proliferation in palmitic acid and oleic acid-induced HepG2 cells compared to the control group. Moreover, our western blot data show that metformin treatment changes apoptosis.

Conclusion: Our results show that metformin inhibits cell viability of steatosis HepG2 cells. These findings may be preliminary for new studies in steatosis HepG2 cells and may provide new therapeutic targets or treatment strategies against hepatocellular carcinoma.

目的:二甲双胍是治疗II型糖尿病的常用推荐药物,有报道称其具有抗癌特性,并可能改善某些恶性肿瘤的预后。流行病学研究表明,使用二甲双胍可以提高癌症患者的生存率。然而,这种现象背后的机制仍然不完全清楚。在我们的研究中,我们的目的是研究二甲双胍如何影响棕榈酸和油酸诱导的肝细胞脂肪变性细胞的增殖和凋亡。方法:利用油酸和棕榈酸诱导HepG2细胞脂质积累,建立非酒精性脂肪肝体外细胞模型。油红O染色观察细胞内脂滴分布。采用BrdU细胞增殖检测试剂盒检测细胞增殖情况。western blot法检测蛋白表达。结果:我们发现与对照组相比,二甲双胍降低了棕榈酸和油酸诱导的HepG2细胞的细胞增殖。此外,我们的western blot数据显示,二甲双胍治疗改变了细胞凋亡。结论:二甲双胍抑制脂肪变性HepG2细胞活力。这些发现可能为脂肪变性HepG2细胞的新研究奠定了基础,并可能为肝癌的治疗提供新的靶点或治疗策略。
{"title":"Effect of metformin on cell proliferation and apoptosis in steatosis HepG2 cell model.","authors":"Ayse Melek Tanriverdi Bademci, Banu Aydin, Hulya Cabadak","doi":"10.14744/nci.2024.49775","DOIUrl":"10.14744/nci.2024.49775","url":null,"abstract":"<p><strong>Objective: </strong>Metformin, which is commonly recommended drug for managing type II diabetes, has been reported to have anti-cancer properties and may improve the prognosis of some malignancies. Epidemiology studies have shown improved survival in cancer patients using metformin. However, the mechanism behind this phenomenon remains incompletely understood. In our study, Our objective was to investigate how metformin influences the proliferation and apoptosis of hepatocellular carcinoma cells induced with steatosis via palmitic acid and oleic acid.</p><p><strong>Methods: </strong>We established an in vitro cellular model of non-alcoholic fatty liver disease by inducing lipid accumulation in HepG2 cells through the use of oleic acid and palmitic acid. Oil Red O staining was conducted to observe the distribution of intracellular lipid droplets. Cell proliferation were detected using the BrdU cell proliferation detection kit. Protein expressions were detected by western blot method techniques.</p><p><strong>Results: </strong>We found that metformin reduced cell proliferation in palmitic acid and oleic acid-induced HepG2 cells compared to the control group. Moreover, our western blot data show that metformin treatment changes apoptosis.</p><p><strong>Conclusion: </strong>Our results show that metformin inhibits cell viability of steatosis HepG2 cells. These findings may be preliminary for new studies in steatosis HepG2 cells and may provide new therapeutic targets or treatment strategies against hepatocellular carcinoma.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"12 4","pages":"509-515"},"PeriodicalIF":0.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of malnutrition in patients with febrile neutropenia. 发热性中性粒细胞减少症患者营养不良的评价。
IF 0.9 Pub Date : 2025-08-11 eCollection Date: 2025-01-01 DOI: 10.14744/nci.2024.44420
Eyup Sami Akbas, Sema Ucak Basak, Ecem Sevim

Objective: Febrile neutropenia is a critical condition in patients with malignancy, requiring oral and/or parenteral antibiotic treatment; and a significant cause of mortality and morbidity. It is well known that nutritional status is excessively impaired in these patients due to underlying disease itself along with the chemotherapeutics used. In this study we investigated nutritional status and general characteristics of patients admitted to our internal medicine clinic with febrile neutropenia.

Methods: Thirty patients who were followed up in the internal medicine service were included in the study. For the analysis of the data of the patients, height, weight, body mass index (BMI), weight loss in the last three months, albümin and total iron binding capacity values were recorded. Hand grip strength, mid-upper arm and mid-calf circumference measurements were obtained for the assessment of muscle strength; Mini Nutritional Assessment (MNA) and Nutrition Risk Screening 2002 (NRS 2002) scores were calculated at admission and discharge to evaluate nutritional status. Multinational Association of Supportive Care in Cancer (MASCC) score was used to identify risk and manage treatment.

Results: We included thirty patients (mean age 58.27±16.52 years, 53% females). Of 30, six patients had lung cancer, four patients had myelodysplastic syndrome, three patients had stomach cancer, two patients had gastrointestinal system lymphoma, two patients had colon cancer, two patients had breast cancer, two patients had Non-Hodgkin's lymphoma.

Conclusion: Majority of the patients, admitted to our internal medicine clinic, with febrile neutropenia were found to be malnourished; regardless of their risk classifications. Nutritional assessment scores of the majority were in the low-risk group. In conclusion, patients hospitalized with febrile neutropenia had poor nutritional status.

目的:发热性中性粒细胞减少症是恶性肿瘤患者的危重症状,需要口服和/或肠外抗生素治疗;也是导致死亡率和发病率的重要原因。众所周知,由于潜在疾病本身以及所使用的化疗药物,这些患者的营养状况严重受损。在这项研究中,我们调查了我们内科门诊收治的发热性中性粒细胞减少症患者的营养状况和一般特征。方法:对30例在内科就诊的患者进行随访。对患者的资料进行分析,记录患者的身高、体重、体质指数(BMI)、近3个月的减重情况、白蛋白含量(albmin)和总铁结合容量(total iron binding capacity)值。手掌握力、上臂中部和小腿中部围度测量用于评估肌肉力量;入院和出院时分别计算Mini Nutrition Assessment (MNA)和Nutrition Risk Screening 2002 (NRS 2002)评分,评估患者的营养状况。跨国癌症支持治疗协会(MASCC)评分用于识别风险和管理治疗。结果:纳入30例患者,平均年龄58.27±16.52岁,女性占53%。在30名患者中,6名患者患有肺癌,4名患者患有骨髓增生异常综合征,3名患者患有胃癌,2名患者患有胃肠道系统淋巴瘤,2名患者患有结肠癌,2名患者患有乳腺癌,2名患者患有非霍奇金淋巴瘤。结论:内科门诊收治的发热性中性粒细胞减少患者以营养不良为主;不管他们的风险等级如何。营养评估得分多数在低危组。综上所述,住院发热性中性粒细胞减少患者营养状况较差。
{"title":"Evaluation of malnutrition in patients with febrile neutropenia.","authors":"Eyup Sami Akbas, Sema Ucak Basak, Ecem Sevim","doi":"10.14744/nci.2024.44420","DOIUrl":"10.14744/nci.2024.44420","url":null,"abstract":"<p><strong>Objective: </strong>Febrile neutropenia is a critical condition in patients with malignancy, requiring oral and/or parenteral antibiotic treatment; and a significant cause of mortality and morbidity. It is well known that nutritional status is excessively impaired in these patients due to underlying disease itself along with the chemotherapeutics used. In this study we investigated nutritional status and general characteristics of patients admitted to our internal medicine clinic with febrile neutropenia.</p><p><strong>Methods: </strong>Thirty patients who were followed up in the internal medicine service were included in the study. For the analysis of the data of the patients, height, weight, body mass index (BMI), weight loss in the last three months, albümin and total iron binding capacity values were recorded. Hand grip strength, mid-upper arm and mid-calf circumference measurements were obtained for the assessment of muscle strength; Mini Nutritional Assessment (MNA) and Nutrition Risk Screening 2002 (NRS 2002) scores were calculated at admission and discharge to evaluate nutritional status. Multinational Association of Supportive Care in Cancer (MASCC) score was used to identify risk and manage treatment.</p><p><strong>Results: </strong>We included thirty patients (mean age 58.27±16.52 years, 53% females). Of 30, six patients had lung cancer, four patients had myelodysplastic syndrome, three patients had stomach cancer, two patients had gastrointestinal system lymphoma, two patients had colon cancer, two patients had breast cancer, two patients had Non-Hodgkin's lymphoma.</p><p><strong>Conclusion: </strong>Majority of the patients, admitted to our internal medicine clinic, with febrile neutropenia were found to be malnourished; regardless of their risk classifications. Nutritional assessment scores of the majority were in the low-risk group. In conclusion, patients hospitalized with febrile neutropenia had poor nutritional status.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"12 4","pages":"430-437"},"PeriodicalIF":0.9,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of area and volume changes in the costoclavicular region in patients treated nonoperatively after mid-shaft clavicle fracture. 锁骨中轴骨折非手术治疗后锁骨区域面积和体积变化的评价。
IF 0.9 Pub Date : 2025-08-08 eCollection Date: 2025-01-01 DOI: 10.14744/nci.2024.42890
Kadir Gulnahar, Muhammet Okkan, Neslihan Buyukmurat, Emre Karadeniz

Objective: The aim of this study is to radiologically compare area and volume changes in the costoclavicular region with the unaffected side in patients treated nonoperatively after unilateral midshaft clavicle fracture and to evaluate functional outcomes.

Methods: This study included 16 patients (14 males, 2 females) with midshaft clavicle fractures who were admitted between 2017-2018 and union was achieved with conservative methods. Magnetic resonance imaging (MRI) of the shoulder including the costoclavicular region was performed after union. Area and volume calculations of the fractured and unaffected costoclavicular region of the patients were performed on the standard MR sections under the guidance of a specialist radiologist. The Short Version of Disabilities of the Arm, Shoulder and Hand (QDASH) score was used for functional assessment. Range of motion was measured on the affected and unaffected sides at the last follow-up visit.

Results: The mean age of the patients was 30.4±20.8 years (5-69) and the mean follow-up was 8.3±1.3 (6-10) months. The mean shortening was 14.3 mm±8.2 (3-29). The area measurements of the costoclavicular region were divided into 3 levels in axillary section: acromioclavicular joint, mid 1/3 of the clavicle, and sternoclavicular joint level. The median area measurements were 1115 (364-3675) mm2, 1495 (365-4199) mm2, and 1201 (197-3812) mm2 on the unaffected side and 895.5 (351-3670) mm2, 1098.5 (340-3191) mm2, and 1037.5 (166-3237) mm2 on the fractured side, respectively (p=0.905, p=0.491, p=0.888). In volume measurements, the median volumes of the unaffected side and the fractured side were 34.3 (10.7-69.7) mm3 and 28.9 (8.1-60.9) mm3, respectively (p=0.268). No significant difference was found in the statistical analysis of area and volume measurements. At the end of the follow-up period, the QDASH score and functional outcome of the patients were good.

Conclusion: Conservative treatment of midshaft clavicle fractures did not result in significant area and volume changes in the costoclavicular region. The inability to clinically demonstrate the theoretical expectation of decreased area and volume on the fractured site suggests that other biomechanical factors are involved in the healing process of the human body.

目的:本研究的目的是影像学比较单侧锁骨中轴骨折非手术治疗的患者肋锁骨区与未受影响侧面积和体积的变化,并评估功能预后。方法:本研究纳入2017-2018年间收治的锁骨中轴骨折患者16例(男14例,女2例),均采用保守方法愈合。骨愈合后进行肩关节包括肋锁骨区的磁共振成像(MRI)。在专业放射科医生的指导下,在标准MR切片上对患者骨折和未受影响的肋锁骨区域进行面积和体积计算。采用短版手臂、肩和手的残疾(QDASH)评分进行功能评估。在最后一次随访时测量受影响侧和未受影响侧的活动范围。结果:患者平均年龄30.4±20.8岁(5 ~ 69岁),平均随访时间8.3±1.3个月(6 ~ 10个月)。平均缩短14.3 mm±8.2(3-29)。腋窝切片将肋锁骨区面积测量分为3个水平:肩锁关节、锁骨中部1/3和胸锁关节水平。未骨折侧的中位面积分别为1115 (364-3675)mm2、1495 (365-4199)mm2和1201 (197-3812)mm2,骨折侧的中位面积分别为895.5 (351-3670)mm2、1098.5 (340-3191)mm2和1037.5 (166-3237)mm2 (p=0.905, p=0.491, p=0.888)。在体积测量中,未受影响侧和骨折侧的中位体积分别为34.3 (10.7-69.7)mm3和28.9 (8.1-60.9)mm3 (p=0.268)。在面积和体积测量的统计分析中没有发现显著差异。随访结束时,患者的QDASH评分和功能结局良好。结论:锁骨中轴骨折保守治疗对肋锁骨区面积和体积无明显影响。无法在临床上证明骨折部位面积和体积减小的理论预期,这表明其他生物力学因素参与了人体的愈合过程。
{"title":"Evaluation of area and volume changes in the costoclavicular region in patients treated nonoperatively after mid-shaft clavicle fracture.","authors":"Kadir Gulnahar, Muhammet Okkan, Neslihan Buyukmurat, Emre Karadeniz","doi":"10.14744/nci.2024.42890","DOIUrl":"10.14744/nci.2024.42890","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to radiologically compare area and volume changes in the costoclavicular region with the unaffected side in patients treated nonoperatively after unilateral midshaft clavicle fracture and to evaluate functional outcomes.</p><p><strong>Methods: </strong>This study included 16 patients (14 males, 2 females) with midshaft clavicle fractures who were admitted between 2017-2018 and union was achieved with conservative methods. Magnetic resonance imaging (MRI) of the shoulder including the costoclavicular region was performed after union. Area and volume calculations of the fractured and unaffected costoclavicular region of the patients were performed on the standard MR sections under the guidance of a specialist radiologist. The Short Version of Disabilities of the Arm, Shoulder and Hand (QDASH) score was used for functional assessment. Range of motion was measured on the affected and unaffected sides at the last follow-up visit.</p><p><strong>Results: </strong>The mean age of the patients was 30.4±20.8 years (5-69) and the mean follow-up was 8.3±1.3 (6-10) months. The mean shortening was 14.3 mm±8.2 (3-29). The area measurements of the costoclavicular region were divided into 3 levels in axillary section: acromioclavicular joint, mid 1/3 of the clavicle, and sternoclavicular joint level. The median area measurements were 1115 (364-3675) mm<sup>2</sup>, 1495 (365-4199) mm<sup>2</sup>, and 1201 (197-3812) mm<sup>2</sup> on the unaffected side and 895.5 (351-3670) mm<sup>2</sup>, 1098.5 (340-3191) mm<sup>2</sup>, and 1037.5 (166-3237) mm<sup>2</sup> on the fractured side, respectively (p=0.905, p=0.491, p=0.888). In volume measurements, the median volumes of the unaffected side and the fractured side were 34.3 (10.7-69.7) mm<sup>3</sup> and 28.9 (8.1-60.9) mm<sup>3</sup>, respectively (p=0.268). No significant difference was found in the statistical analysis of area and volume measurements. At the end of the follow-up period, the QDASH score and functional outcome of the patients were good.</p><p><strong>Conclusion: </strong>Conservative treatment of midshaft clavicle fractures did not result in significant area and volume changes in the costoclavicular region. The inability to clinically demonstrate the theoretical expectation of decreased area and volume on the fractured site suggests that other biomechanical factors are involved in the healing process of the human body.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"12 4","pages":"490-495"},"PeriodicalIF":0.9,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of two analgesia applied to periprostatic nerve blockage during transrectal ultrasound guided prostate biopsy. 经直肠超声引导前列腺活检术中前列腺周围神经阻塞两种镇痛方法的比较。
IF 0.9 Pub Date : 2025-08-08 eCollection Date: 2025-01-01 DOI: 10.14744/nci.2024.79577
Halil Cagri Aybal, Taha Numan Yikilmaz, Halil Basar

Objective: A combination of local anesthetic treatments provides better pain alleviation than periprostatic nerve block (PPNB) alone during a prostate biopsy procedure. The primary objective of this study was to compare Visual Analog Scale (VAS) pain levels during transrectal ultrasound (TRUS)- guided prostate biopsy whilst the use of prilocaine-lidocaine cream, diclofenac suppository, or PPNB only in a prospective, randomized study.

Methods: This study included 162 patients who had TRUS-guided prostate biopsies performed at the Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Center within a 6 month period, from April to October 2017. Three groups of patients were randomly assigned: group 1 underwent PPNB plus prilocaine-lidocaine cream, group 2 received diclofenac suppository along with PPNB, and group 3 underwent PPNB alone. The VAS was used to measure the degree of pain: VAS 1 was used to record the pain at the time the ultrasound probe was inserted, VAS 2 was used to document the pain during PPNB, and VAS 3 was used to record the pain during needle biopsy. Following the biopsy, any complications or negative consequences were recorded.

Results: Mean age or serum prostate specific antigen (PSA) levels were similar between the three groups. The VAS 1, VAS 2, and VAS 3 pain scores showed statistically significant difference among the three groups (p=0.001). Between groups 1 and 2, there was a statistically significant difference in VAS 1 pain scores (p=0.01). There was no statistically difference in VAS 2 and VAS 3 pain scores between the groups 1 and 2 (p=0.08 and p=0.23, respectively). Patients between the groups 3 and other groups had significantly difference in VAS pain scores (p<0.05).

Conclusion: In this study, we highlight that when applied as an adjuvant to PPNB, either 5% prilocaine-lidocaine cream or a 100 mg diclofenac suppository reduced pain levels relative to PPNB alone. When compared to a 100 mg diclofenac suppository, prilocaine-lidocaine cream significantly reduces pain during the insertion and manipulation of the ultrasound probe.

目的:在前列腺活检过程中,局部麻醉联合治疗比单独前列腺周围神经阻滞(PPNB)能更好地缓解疼痛。本研究的主要目的是在一项前瞻性随机研究中比较经直肠超声(TRUS)引导下前列腺活检期间视觉模拟量表(VAS)疼痛水平,同时仅使用普丙卡因-利多卡因乳膏、双氯芬酸栓剂或PPNB。方法:本研究纳入162例患者,这些患者于2017年4月至10月6个月期间在Dr. Abdurrahman Yurtaslan Ankara肿瘤学培训和研究中心接受了trus引导的前列腺活检。随机分为三组患者:第一组采用PPNB联合普丙卡因-利多卡因乳膏,第二组采用双氯芬酸栓剂联合PPNB,第三组单独采用PPNB。采用VAS测量疼痛程度:VAS 1用于记录超声探头插入时的疼痛,VAS 2用于记录PPNB过程中的疼痛,VAS 3用于记录穿刺活检过程中的疼痛。活检后,记录任何并发症或不良后果。结果:三组患者的平均年龄和血清前列腺特异性抗原(PSA)水平相似。三组患者VAS 1、VAS 2、VAS 3疼痛评分差异有统计学意义(p=0.001)。1、2组患者VAS 1疼痛评分比较,差异有统计学意义(p=0.01)。两组患者VAS 2、VAS 3疼痛评分比较,差异均无统计学意义(p=0.08、p=0.23)。结论:在本研究中,我们强调,当作为PPNB的辅助用药时,5%的丙胺卡因-利多卡因乳膏或100mg双氯芬酸栓剂相对于单独使用PPNB都能降低疼痛水平。与100mg双氯芬酸栓剂相比,普利卡因-利多卡因乳膏可显著减轻超声探头插入和操作过程中的疼痛。
{"title":"Comparison of two analgesia applied to periprostatic nerve blockage during transrectal ultrasound guided prostate biopsy.","authors":"Halil Cagri Aybal, Taha Numan Yikilmaz, Halil Basar","doi":"10.14744/nci.2024.79577","DOIUrl":"10.14744/nci.2024.79577","url":null,"abstract":"<p><strong>Objective: </strong>A combination of local anesthetic treatments provides better pain alleviation than periprostatic nerve block (PPNB) alone during a prostate biopsy procedure. The primary objective of this study was to compare Visual Analog Scale (VAS) pain levels during transrectal ultrasound (TRUS)- guided prostate biopsy whilst the use of prilocaine-lidocaine cream, diclofenac suppository, or PPNB only in a prospective, randomized study.</p><p><strong>Methods: </strong>This study included 162 patients who had TRUS-guided prostate biopsies performed at the Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Center within a 6 month period, from April to October 2017. Three groups of patients were randomly assigned: group 1 underwent PPNB plus prilocaine-lidocaine cream, group 2 received diclofenac suppository along with PPNB, and group 3 underwent PPNB alone. The VAS was used to measure the degree of pain: VAS 1 was used to record the pain at the time the ultrasound probe was inserted, VAS 2 was used to document the pain during PPNB, and VAS 3 was used to record the pain during needle biopsy. Following the biopsy, any complications or negative consequences were recorded.</p><p><strong>Results: </strong>Mean age or serum prostate specific antigen (PSA) levels were similar between the three groups. The VAS 1, VAS 2, and VAS 3 pain scores showed statistically significant difference among the three groups (p=0.001). Between groups 1 and 2, there was a statistically significant difference in VAS 1 pain scores (p=0.01). There was no statistically difference in VAS 2 and VAS 3 pain scores between the groups 1 and 2 (p=0.08 and p=0.23, respectively). Patients between the groups 3 and other groups had significantly difference in VAS pain scores (p<0.05).</p><p><strong>Conclusion: </strong>In this study, we highlight that when applied as an adjuvant to PPNB, either 5% prilocaine-lidocaine cream or a 100 mg diclofenac suppository reduced pain levels relative to PPNB alone. When compared to a 100 mg diclofenac suppository, prilocaine-lidocaine cream significantly reduces pain during the insertion and manipulation of the ultrasound probe.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"12 4","pages":"419-424"},"PeriodicalIF":0.9,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497900/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological study of congenital myasthenic syndromes based on national electronic health database of Turkiye. 基于土耳其国家电子健康数据库的先天性肌无力综合征流行病学研究。
IF 0.9 Pub Date : 2025-08-08 eCollection Date: 2025-01-01 DOI: 10.14744/nci.2025.08455
Berin Inan, Bilgin Ozturk, Naim Ata, Esra Taskiran, Suayip Birinci, Riza Sonkaya, Erdal Eroglu, Omer Karadas, Ersin Tan, Zeki Odabasi

Objective: Congenital myasthenic syndromes (CMS) represent a group of genetically heterogenous disorders characterized by defective signal transmission at the neuromuscular junction. Although global prevalence of CMS remains uncertain, regional studies have reported varying prevalence rates. This study aimed to define the incidence and prevalence of CMS in Turkiye utilizing data from the national electronic health registry. Additionally, the rate of pyridostigmine prescriptions among patients with CMS was assessed.

Methods: The study was a retrospective national cohort study, and patients with at least three G70.2 ICD-10 code entries between 1 January 2015 and 22 May 2024 were included. While calculating incidence and prevalence rates official census data from the Turkish Statistical Institute were used.

Results: A total of 406 patients were included in the study, with females comprising 48.8% of the cohort. The mean age at diagnosis was 20.59±21.65 years (median: 12.00, min-max: 0-86). Among the cohort, 58.6% were diagnosed before the age of 18, and 12.3% before the age of one. Pyridostigmine was prescribed at least once to 68.2% of the patients. The annual incidence of CMS ranged from 0.28 to 0.59 per million between 2016 and 2023. In 2023, the incidence and prevalence rates of CMS were calculated as 0.63 and 4.49 per million, respectively.

Conclusion: This study represents the first comprehensive nationwide epidemiological analysis of CMS in Turkiye utilizing the national electronic health registry. The study enhances the understanding of the epidemiological landscape of CMS in the country by reporting the current incidence, prevalence, and pyridostigmine prescription rates and underscores the significance of this rare but impactful neuromuscular disorder.

目的:先天性肌无力综合征(CMS)是一组以神经肌肉交界处信号传递缺陷为特征的遗传异质性疾病。虽然CMS的全球患病率仍不确定,但区域研究报告了不同的患病率。本研究旨在利用国家电子健康登记处的数据确定土耳其CMS的发病率和患病率。此外,评估CMS患者吡哆斯的明处方率。方法:该研究是一项回顾性国家队列研究,纳入了2015年1月1日至2024年5月22日期间至少有3个G70.2 ICD-10编码条目的患者。在计算发病率和流行率时,使用了土耳其统计研究所的官方普查数据。结果:共纳入406例患者,其中女性占48.8%。平均诊断年龄为20.59±21.65岁(中位数:12.00,最小最大值:0-86)。在队列中,58.6%的患者在18岁前确诊,12.3%的患者在1岁前确诊。68.2%的患者至少开过一次吡哆斯的明。2016年至2023年间,CMS的年发病率在0.28 - 0.59 /百万之间。2023年CMS的发病率和患病率分别为0.63 /百万和4.49 /百万。结论:本研究首次利用国家电子健康登记系统对土耳其CMS进行了全面的全国流行病学分析。该研究通过报告目前的发病率、流行率和吡哆斯的明处方率,增强了对该国CMS流行病学概况的了解,并强调了这种罕见但影响严重的神经肌肉疾病的重要性。
{"title":"Epidemiological study of congenital myasthenic syndromes based on national electronic health database of Turkiye.","authors":"Berin Inan, Bilgin Ozturk, Naim Ata, Esra Taskiran, Suayip Birinci, Riza Sonkaya, Erdal Eroglu, Omer Karadas, Ersin Tan, Zeki Odabasi","doi":"10.14744/nci.2025.08455","DOIUrl":"10.14744/nci.2025.08455","url":null,"abstract":"<p><strong>Objective: </strong>Congenital myasthenic syndromes (CMS) represent a group of genetically heterogenous disorders characterized by defective signal transmission at the neuromuscular junction. Although global prevalence of CMS remains uncertain, regional studies have reported varying prevalence rates. This study aimed to define the incidence and prevalence of CMS in Turkiye utilizing data from the national electronic health registry. Additionally, the rate of pyridostigmine prescriptions among patients with CMS was assessed.</p><p><strong>Methods: </strong>The study was a retrospective national cohort study, and patients with at least three G70.2 ICD-10 code entries between 1 January 2015 and 22 May 2024 were included. While calculating incidence and prevalence rates official census data from the Turkish Statistical Institute were used.</p><p><strong>Results: </strong>A total of 406 patients were included in the study, with females comprising 48.8% of the cohort. The mean age at diagnosis was 20.59±21.65 years (median: 12.00, min-max: 0-86). Among the cohort, 58.6% were diagnosed before the age of 18, and 12.3% before the age of one. Pyridostigmine was prescribed at least once to 68.2% of the patients. The annual incidence of CMS ranged from 0.28 to 0.59 per million between 2016 and 2023. In 2023, the incidence and prevalence rates of CMS were calculated as 0.63 and 4.49 per million, respectively.</p><p><strong>Conclusion: </strong>This study represents the first comprehensive nationwide epidemiological analysis of CMS in Turkiye utilizing the national electronic health registry. The study enhances the understanding of the epidemiological landscape of CMS in the country by reporting the current incidence, prevalence, and pyridostigmine prescription rates and underscores the significance of this rare but impactful neuromuscular disorder.</p>","PeriodicalId":94347,"journal":{"name":"Northern clinics of Istanbul","volume":"12 4","pages":"468-474"},"PeriodicalIF":0.9,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497907/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145246220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Northern clinics of Istanbul
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1